Bone marrow micrometastases in advanced stage non-small cell lung carcinoma patients

A generic diagnosis of ‘small cell or non-small cell carcinoma’ was sufficient in the past when there was no clinical demand for sub classification as it had no impact on therapy. Patients with advanced stage non-small cell lung carcinoma who received chemotherapy were typically treated with a ‘platinum doublet’ of cisplatin plus gemcitabine irrespective of histological subtype. At present, in contrast, sub classification of non-small cell lung carcinoma has significant treatment implications, especially for advanced stage tumors for which chemotherapy or targeted therapy is being considered. Consequently, pathologists are asked to subtype the tumor. The demand for sub typing is driven by oncologists, who now have several new targeted therapies, the efficacy of which varies by histological subtype. In view of demand of sub typing of lung carcinomas as well as the guidelines given by WHO 2015 classification which emphasises the importance of a separate classification for biopsies and cytology on one side and the resection specimen on the other, we have taken up this study. Keywords: Lung carcinoma, classification, core biopsies, immunohistochemistry

Download Full-text

Detection of tumor specific gene expression in bone marrow and peripheral blood from patients with small cell lung carcinoma

Cancer ◽

10.1002/cncr.11108 ◽

2003 ◽

Vol 97 (4) ◽

pp. 1057-1062 ◽

Cited By ~ 4

Author(s):

Masato Shingyoji ◽

Yuichi Takiguchi ◽

Reiko Watanabe ◽

Kenzo Hiroshima ◽

Ken Motoori ◽

...

Keyword(s):

Gene Expression ◽

Bone Marrow ◽

Lung Carcinoma ◽

Peripheral Blood ◽

Small Cell Lung Carcinoma ◽

Small Cell ◽

Specific Gene ◽

Small Cell Lung ◽

Cell Lung Carcinoma ◽

Specific Gene Expression

Download Full-text

Radionuclide imaging of bone marrow metastases with a Tc-99m labeled monoclonal antibody to small cell lung carcinoma

Lung Cancer ◽

10.1016/0169-5002(92)90161-c ◽

1992 ◽

Vol 8 (2) ◽

pp. 131

Keyword(s):

Monoclonal Antibody ◽

Bone Marrow ◽

Radionuclide Imaging ◽

Lung Carcinoma ◽

Small Cell Lung Carcinoma ◽

Small Cell ◽

Small Cell Lung ◽

Cell Lung Carcinoma ◽

Bone Marrow Metastases

Download Full-text

Prognostic significance of PD-L1 in advanced non-small cell lung carcinoma patients: a cohort study at a single institute

10.21203/rs.2.15718/v1 ◽

2019 ◽

Author(s):

Yanjie Zhao ◽

Feng Shi ◽

Quan Zhou ◽

Yuchen Li ◽

Jiangping Wu ◽

...

Keyword(s):

Cohort Study ◽

Lung Carcinoma ◽

Small Cell Lung Carcinoma ◽

Prognostic Significance ◽

Small Cell ◽

Advanced Stage ◽

Small Cell Lung ◽

Ki 67 ◽

Cell Lung Carcinoma ◽

Expression Status

Abstract Background This study aimed to investigate the prognostic effect of PD-L1 on Chinese non-small cell lung carcinoma patients.Methods A retrospective cohort study was conducted and consecutively recruited 97 patients with non-small cell lung carcinoma. The expression status of PD-1, PD-L1, p53 and Ki-67 was detected by immunohistochemistry. Kaplan-Meier survival curve with log-rank test was used to estimate survival. Cox-Hazard Proportion regression model was used to estimate the hazard ratio and 95% confidence intervalResults The median tumor size was 3.5 cm and 2.0 cm among patients with positive and negative PD-L1 expression, respectively (p<0.001). The proportion of patients with positive and negative PD-L1 expression having nerve invasion was 26.3% and 5.0% (p<0.01). 47.4% patients with positive PD-L1 expression had blood vessel invasion compared with 20.0% patients with negative PD-L1 expression (p<0.01). 64.9% patients with positive PD-L1 expression had lymph node metastasis compared with 27.5% patients with negative PD-L1 expression (p<0.001). Patients with positive PD-L1 expression were more likely to be in advanced stage (p<0.001) and had higher Ki-67 index (p<0.01). PD-L1 expression status did not show any significant association with DFS or OS. However among advanced patients, HR of PD-L1 expression was 4.13 (95%CI 1.06, 16.12).Conclusions Positive PD-L1 expression is associated with poorer prognosis in advanced stage patients. Compare to patients with negative expression, patients with positive PD-L1 expression had more aggressive pathological features. Further prospective studies are needed to confirm the results.

Download Full-text

Rapid Arc-SBRT: Non-invasive immune adjuvant for advanced stage Non-Small Cell Lung Carcinoma

Anti-Cancer Agents in Medicinal Chemistry ◽

10.2174/1871520621666210322105641 ◽

2021 ◽

Vol 21 ◽

Author(s):

Arun Chairmadurai ◽

Sandeep K. Jain ◽

Aklank Jain ◽

Hridayesh Prakash

Keyword(s):

Lung Carcinoma ◽

Early Stage ◽

Small Cell Lung Carcinoma ◽

Small Cell ◽

Advanced Stage ◽

Small Cell Lung ◽

Cell Lung Carcinoma ◽

Normal Tissues ◽

Metastatic Lesions ◽

Immune Adjuvant

: In conjunction with Radio-chemotherapy, pulmonary resection is recommended for early-stage Non-small-cell lung carcinoma but not for advanced-stage NSCLC patients with having high-grade metastatic lesions. In these cases, Rapid Arc-Stereotactic body radiotherapy (Ra-SBRT) technique offers a therapeutic advantage by delivering focal irradiation to metastatic lung lesions and reduces the bystander toxicity to normal tissues. We have previously demonstrated that Ra-SBRT ablates metastatic lesions and induces tumor immune rejection of metastatic tumors by promoting in situ programming of M2 TAM towards M1-TAM and infiltration of Siglec-8+ Eosinophils. Most interestingly, Ra SBRT has very low abscopal impact and spares normal tissues, which are the significant limitations with conventional radiotherapy. In view of this and Immune adjuvant potential of Ra SBRT, it promotes normalization of aberrant vasculature and inhibits the metastatic potential of NSCLC lesions. In view of this we here propose that Ra-SBRT indeed represents an immunogenic approach for the effective management of advanced-stage NSCLC.

Download Full-text